Skip to main content

Table 1 Adverse events occurring in 10% of patients or more in the pivotal study of single-agent rituximab in relapsed andrefractory indolent lymphoma

From: Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis

 

Number of patients

 

Adverse event

Grade 1/2

Grade 3

Grade 4

%

Fever

84

-

-

43

Chills

51

2

-

28

Nausea

34

1

-

18

Headache

26

1

-

14

Angio-oedema

27

1

-

14

Asthenia

25

-

-

13

Pruritus

21

1

-

13

Pain

22

-

-

11

Rash

16

-

-

10

Hypotension

18

1

-

10

Anaemia

1

1

-

10

  1. From McLaughlin and coworkers [13]. Reprinted with permission from the American Society of Clinical Oncology.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us